Xining, Aug 25, 2026 — Qinghai Province’s Center for Disease Control and Prevention released the second batch of expert demonstration results for its 2026 non-immunization vaccine procurement expansion, clearing three influenza vaccine products for online platform listing after a July 8 expert review session.
Procurement Roster
| No. | Generic Name | Dosage Form | Specification | Packaging | Manufacturer | Applicant | Price (CNY) |
|---|---|---|---|---|---|---|---|
| 1 | Influenza Virus Split Vaccine | Injection | 0.5 ml/vial | Vial | Hualan Biological Vaccine Inc. | Hualan Biological Vaccine Inc. | 78.00 |
| 2 | Influenza Virus Split Vaccine | Injection | 0.25 ml/dose | Pre-filled Syringe | Hualan Biological Vaccine Inc. | Hualan Biological Vaccine Inc. | 68.00 |
| 3 | Influenza Virus Subunit Vaccine | Injection | 0.5 ml/dose | Pre-filled Syringe | Zhongyi Anke Biotechnology Co., Ltd. | Zhongyi Anke Biotechnology Co., Ltd. | 268.00 |
Regulatory Context
The results follow Qinghai CDC Bureau [2025] No. 39, the provincial implementation plan for centralized online procurement of non-immunization vaccines. The review process encompassed enterprise application, documentation screening, on-site price negotiation, and expert panel certification. All three products were deemed compliant after supplementary materials were submitted. The public comment window runs from Aug 25 to Sept 1, 2026.
Market Impact Analysis
The inclusion of two Hualan Biological split-virus influenza vaccines and one Zhongyi Anke subunit formulation expands Qinghai’s elective flu vaccine portfolio ahead of the autumn immunization season. Hualan’s dual-format offering—vial and pre-filled syringe at 78 yuan and 68 yuan respectively—targets different age groups and procurement budgets, while Zhongyi Anke’s premium subunit vaccine at 268 yuan positions itself as a high-efficacy alternative in a province where vaccine access has historically been constrained by logistics and cold-chain infrastructure.
The 68-yuan to 268-yuan price spread reflects a tiered market strategy, allowing public health facilities to match vaccine selection to patient affordability and clinical indication. For manufacturers, securing slots on Qinghai’s non-immunization procurement platform guarantees formulary access across the province’s public vaccination network, a critical channel in a region with limited private clinic penetration.
Forward-Looking Statement
Industry analysts expect the three products to clear the one-week public comment period without material objections, enabling formal platform listing before the peak flu vaccination window opens in October. The July expert review and August publication timeline suggest Qinghai is front-loading its non-immunization vaccine procurement calendar, potentially signaling earlier-than-usual provincial tendering cycles for 2026. Hualan Biological’s dominant position in this batch—two of three slots—reinforces its standing in China’s seasonal flu vaccine market, while Zhongyi Anke’s subunit entry at a 3.4x price premium tests demand elasticity for advanced influenza formulations in western China.-China Health Reform Pulse
Policy Source: https://www.qhcdc.org.cn/xwzx/tzgg/content_3900